17:30

Chairs: Christina PSOMAS, European Hospital, Marseille, France Annemarie WENSING, University Medical Center Utrecht, Netherlands Moderator: Tristan BARBER, Royal Free London NHS Foundation Trust, London, England

HIV and COVID-19 / VIH et COVID-19
Christoph SPINNER, Munich, Germany

Research pitfalls; what COVID has taught us / Les pièges de la recherche : ce que le COVID-19 nous apprend
Laura WATERS, London, England

18:45

Chairs: Sabine KINLOCH, Institute of Immunity & Transplantation, London, England Jean-Pierre ROUTY, McGill University Health Centre, Montreal, Canada

Therapeutic simplification strategies in HIV infection and new ART strategies (2DR, triple regimen) / La simplification des stratégies thérapeutiques et les stratégies antirétrovirales chez les patients atteints par le VIH (2DR, triple regimen)
Jeff MURRY, Foster City, USA

Dual therapy against tritherapy: inflammation Vs toxicity / Les bithérapies contre les trithérapies : inflammation Vs toxicité
Christina PSOMAS, Marseille, France
Casper ROKX, Rotterdam, the Netherlands

20:00

Chairs: Guido POLI, Vita-Salute San Raffaele University, Milano, Italy Santiago MORENO, Hospital Ramón y Cajal, Madrid, Spain

O1. Impact of early antiretroviral therapy on tissue resident myeloid cells in the liver and lung of SIV-infected rhesus macaques
Authors: J. CLAIN, H. RABEZANAHARY, G. RACINE, G. BENMADID-LAKTOUT, O. ZGHIDI-ABOUZID, J. ESTAQUIER
Quebec University Hospital, Laval University, Research Center, Quebec - Canada

O2. Sexual satisfaction in women living with HIV. Are they the forgotten ones?
Authors: L. GONZÁLEZ RODRÍGUEZ¹, J. BALIÑAS², R. SCHULTZE³, L. LABAJO³, M.D.G. MUÑOZ³, Á. MENA^2
1Obstetrics And Gynecology Service, Álvaro Cunqueiro University Hospital, Vigo - Spain
²Infectious Pathology Unit, A Coruña University Complex, A Coruña - Spain
³Infectious Pathology Unit, Álvaro Cunqueiro University Hospital, Vigo - Spain

O3. Influence of Hepatitis E virus genetic variability on the viral circulation between humans and environment
Authors: E. SCHVOERER1, C. HARTARD¹, H. FENAUX¹, A. DE ROUGEMONT², E. LAUGEL¹, S. BERGER¹,J.P. BRONOWICKI³, I. BERTRAND^4
1Nancy University Hospital, Laboratory of Virology, Vandœuvre-Lès-Nancy - France
²Dijon University Hospital, Laboratory of Virology, Dijon - France
³Nancy University Hospital, Hepato-Gastroenterology, Vandoeuvre Les Nancy - France
⁴ Lcpme (laboratoire De Chimie Physique Et Microbiologie Pour Les Matériaux Et L'environnement), Umr 7564Cnrs-Ul, Campus Santé Brabois, Vandoeuvre Les Nancy - France

O4. Effect of Metformin in non-diabetic people living with HIV: weight loss, decrease in inflammation and modification of the gut microbiota
Authors: S. ISNARD¹, J. LIN¹, T. VARIN², A. MARETTE², D. PLANAS³, C. VAN DER LEY⁴, P. ANCUTA³, J.P. ROUTY^1
1Mcgill University Health Centre, Montreal - Canada
²Laval University, Québec - Canada
³ Montreal University, Montreal - Canada
⁴University Of Groningen, Groningen - Netherlands

O5. Extensive proteomic and transcriptomic changes quench the TCR/CD3 activation signal in latently HIV-1 infected T cells
Authors: E. CARLIN, B. GREER, A. DUVERGER, F. WAGNER, D. MOYLAN, A. DALECKI, S. SABBAJ, O. KUTSCH UAB, Birmingham - United States

DP1. Tracing the patterns of HIV-1 transmission among individuals with different diagnosis status in Greece
Authors: E-G. KOSTAKI¹, S. LIMNAIOS¹, S. PATRINOS², D. CHATZIDIMITRIOU³, G. MAGIORKINIS¹, L. SKOURA³, V. SYPSA¹, A. HATZAKIS¹, D. PARASKEVIS^1
1Department Of Hygiene, Epidemiology And Medical Statistics, Medical School, National And Kapodistrian University Of Athens, Athens - Greece
²Hellenic Center For Diseases Control And Prevention, Marousi - Greece
³ National Aids Reference Center Of Northern Greece, Department Of Microbiology, Aristotle University Medical School, Thessaloniki - Greece

DP2. Identification of fast-growing HIV-1 transmission clusters in Spain and its potential application in Public Health
Authors: H. GIL, E. DELGADO, S. BENITO, M. SÁNCHEZ, J. CAÑADA, E. GARCÍA-BODAS, M.M. THOMSON,
Spanish group for the study of new HIV diagnoses
National Microbiology Centre. Carlos III Health Institute, Majadahonda - Spain

DP3. No impact of SARS-CoV-2 on the Activation Status of ART+HIV+ Patients
Authors: M. NIKOLOVA¹, R. EMILOVA¹, Y. TODOROVA¹, N. YANCHEVA², I. ALEXIEV³, R. GROZDEVA², D. STRASHIMIROV²,N. KUYCHUKOVA^2
1Nrl Of Immunology, National Centre Of Infectious And Parasitic Diseases, Sofia - Bulgaria
²Specialized Hospital for Active Treatment of Infectious and Parasitic Diseases, Sofia - Bulgaria3Nrl Of HIV, National Center of Infectious and Parasitic Diseases, Sofia - Bulgaria

DP4. Factors associated with willingness to participate in end-of-life cure research: perspectives from People Living with HIV
Authors: D. LESSARD¹, M. BILODEAU², P. KEELER³, J.P. ROUTY⁴, E.A. COHEN⁵, K. DUBÉ⁶, B. LEBOUCHɹ,C. COSTINIUK^4
1Canadian Institutes Of Health Research Strategy For Patient-Oriented Research Mentorship Chair In Innovative Clinical Trials, Montreal - Canada
²Ontario Aids Network, Toronto - Canada
³Aids Community Care Montreal, Montreal - Canada
⁴Research Institute of the Mcgill University Health Centre, Montreal - Canada
⁵Montreal Institute of Clinical Research, Department of Microbiology, Infectiology and Immunology, Montreal University,Montreal - Canada
⁶Public Health Leadership Program, University Of North Carolina At Chapel Hill And Chapel Hill And Gilings School Of Global Public Health, Chapel Hill - USA

DP5. Fibrosis regression in HIV-HCV coinfected patients treated by DAAs
Authors: G. LAURICHESSE¹, P. JAFFEUX², A. MIRAND³, N. MROZEK¹, M. VIDAL¹, V. CORBIN¹, H. LAURICHESSE¹,C. JACOMET^1
1Clermont-Ferrand University Hospital, Infectious Diseases, Clermont-Ferrand - France
²Clermont-Ferrand University Hospital, Statistics, Clermont-Ferrand - France
³Clermont-Ferrand University Hospital, Virology, Clermont-Ferrand - France

DP6. Differential Serotyping of HEV genotype 1 and 3
Authors: M. SHATA¹, E. ABDEL-HAMEED¹, S. ROUSTER¹, H. HETTA², K. SHERMAN^3
1University of Cincinnati, Cincinnati - USA
²Department of Medical Microbiology and Immunology, Faculty of Medicine,Assiut University, Assiut - Egypt
³University of Cincinnati, Internal Medicine, Digestive Dis., Cincinnati - USA

17:00

Moderator: Diana FINZI, National Institute of Health, Bethesda, USA Jean-Pierre ROUTY, McGill University Health Centre, Montreal, Canada

Vaccines update for HIV and immunosuppressed patients / Calendrier vaccinal pour les PVVIH et les patients immunodéprimés
Anna-Maria GERETTI, London, England

Post-infection Vs post-vaccinal SARS-CoV-2 immunity: challenges and reality / Post-infection Vs l’immunité acquise grâce au vaccin : défi et réalité
Olivier SCHWARTZ, Paris, France

18:15

Moderator: Jonathan Schapiro, Sheba, ISR

Welcome and introduction
Jonathan Schapiro, Sheba, ISR

Future of NNRTIs: State of the ART of NNRTI resistance
Jonathan Schapiro, Sheba, ISR

Tailoring care for the body
Paddy Mallon, Dublin, IRL

Tailoring care for women with HIV
Karine Lacombe, Paris, FRA

Q&A

19:30

Chairs: Jose Ignacio BERNARDINO, La Paz University Hospital, Madrid, Spain Christina PSOMAS, European Hospital, Marseille, France

The microbiome / Le microbiome
Sergio SERRANO VILLAR, Madrid, Spain

NASH and obesity and weight gain in hepatitis and HIV / La NASH chez les personnes atteintes par une hépatite ou par le VIH
Paddy MALLON, Dublin, Ireland

Role of hepatotropic viruses in the pathogenesis of cancer in PLWH / Le rôle des virus hépatotropes dans la pathogénèse du cancer chez les PVVIH
Alvaro MENA, Coruna, Spain

O6. Myocardial abnormailties in HIV: Insights from Cardiac Magnetic Resonacne Imaging (MRI)
Authors: G. MANMATHAN¹, L. CHACKO², R. MURKI², T. KOTECHA², C. LITTLE², T. BARBER¹,S. KINLOCH¹, M. JOHNSON¹, R. RAKHIT^2
1Royal Free Hospital, London - United Kingdom
²University College London, London - United Kingdom

O7. Cardiomyopathy, pulmonary hypertension and myocarditis not as prevalent in well controlled
HIV: H-ART to Heart study
Authors: G. MANMATHAN, N. NGWU, J. JOHNSON, C. LITTLE, T. KOTECHA, M. JOHNSON, R. RAKHIT
Royal Free Hospital, London - United Kingdom

DP7. Nlrp3 inflammasome activation in peripheral blood leukocytes from HIV-infected patients and its contribution to chronic inflammation
Authors: V. NUNES CORDEIRO LEAL, E.C. DOS REIS, A. PONTILLO
University Of Sao Paulo, Sao Paulo - Brazil

17:00

Chairs: Caroline SABIN, Royal Free Campus, London - England Christina PSOMAS, European Hospital, Marseille, France

London experience / L’expérience londonienne
Alison BROWN, London, England

Fast track cities, where are we? / Les fast-track cities : où en sommes-nous ?
Bertrand AUDOIN, Paris, France

18:15

Moderator: Christina Psomas

Inflammation and Immune markers
Christina Psomas, Montpellier, FRA

Sleep disorders and depression
Anne Moroy, Lille, FRA

Prevention and management of drug drug interactions
Olivier Robineau, Tourcoing, FRA

19:30

Chairs: Valérie POURCHER, Hôpital de la Pitié-Salpêtrière, Paris, France Hervé TISSOT DUPONT, Aix-Marseille University, Marseille, France

Neurological complications of COVID-19, in acute disease and long-term / Les complications neurologiques de la COVID-19, dans les maladies aiguës et au long cours
Arvid EDÉN, Gothenburg, Sweden

Genetic determinants of COVID-19 disease severity / Les déterminants génétiques qui ont un impact sur la gravité de la COVID-19
Manuel CORPAS, Cambridge, England

DP8. Viral rebound (VR) 14 years after discontinuation of antiretroviral therapy (ART)
Authors: S. KINLOCH-DE LOES¹, L. VANDEKERCKHOVE², F. BURNS³, M. JOHNSON^1
1Royal Free Hospital, London - United Kingdom
²University of Ghent, Ghent - Belgium
³Ucl, London - United Kingdom

DP9. Frailty phenotype is associated with antiretroviral exposure among older persons living with HIV
Authors: G. FELKER1, P. ENEL¹, N. PETIT¹, I. RAVAUX¹, A. DARQUE¹, F. RETORNAZ²
sup¹Public University Hospital of Marseille, Marseille - France
²Department Of Public Health, Self-Perceived Health Assessment Research Unit Ea3279,Aix-Marseille University, Marseille - France

17:00

Chairs: Stephano VELLA, Superior Health Institute, Rome, Italy Ferdinand WIT, Academic Medical Center Amsterdam, Netherlands

HIV and global health in the era of coronavirus
Stefano VELLA, Rome, Italy

HTLV-1 has become a new STI
Carmen DE MENDOZA, Madrid, Spain

18:15

Moderator: Christine KATLAMA, Paris, FRA

Dual therapies: what are the impacts on HIV reservoirs? / Bithérapies : quels sont les impacts sur les réservoirs du VIH ?
Véronique Avettand-Fenoel. MCU-PH - UNIVERSITE PARIS , CHU Necker-Enfants Malades, Paris, FRA

What is the impact of long term dual therapy on bone, renal,inflammation and metabolics? / Quel est l'impact de la bithérapie à long terme sur l'os, le rein,l'inflammation et le métabolisme ?
Laura Waters, FRCP MD. Mortimer Market Centre, CNWL, London, UK

19:30

Chairs: Patricia ENEL, Aix-Marseille University, Marseille, France Patrick PHILIBERT, European Hospital, Marseille, France

Impact of COVID on sexual behaviour/risks/testing/ L'impact de la COVID sur les comportements/risques/essais sexuels
Cath MERCER, London, England

New challenges in STIs: M. Genitalium, XDR N.gonorrhoeae / Les nouveaux défis parmi les IST : M. Genitalium, XDR N.gonorrhoeae
Vicente SORIANO, Madrid, Spain

O8. Sexual Transmission of HTLV-1 and expanded spectrum of clinical manifestations
Authors: V. SORIANO¹, J.M. RAMOS², H. PINARGOTE², C. DE MENDOZA³, A. SPANISHH T L V NETWORK^3
1Unir Health Sciences School & Medical Center, Madrid - Spain
²General University Hospital & Miguel Hernandez University, Alicante - Spain
³Puerta De Hierro University Hospital & San Pablo University-Ceu, Madrid - Spain

DP10. HIV-2 in Spain - steadily increasing and new challenges
Authors: V. SORIANO¹, T. CABEZAS², E. CABALLERO³, A.B. LOZANO², C. DE MENDOZA^4
1Unir Health Sciences School & Medical Center, Madrid - Spain
²Hospital De Poniente, Almeria - Spain
³Hospital Vall D'hebron, Barcelona - Spain
⁴Puerta De Hierro Research Institute, Madrid - Spain